MARKET

SAVA

SAVA

Cassava Sciences
NASDAQ
2.080
+0.050
+2.46%
Opening 11:32 02/09 EST
OPEN
2.020
PREV CLOSE
2.030
HIGH
2.080
LOW
1.980
VOLUME
180.72K
TURNOVER
--
52 WEEK HIGH
4.980
52 WEEK LOW
1.150
MARKET CAP
100.48M
P/E (TTM)
-0.9464
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SAVA last week (0202-0206)?
Weekly Report · 9h ago
Weekly Report: what happened at SAVA last week (0126-0130)?
Weekly Report · 02/02 09:35
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 01/28 21:05
Weekly Report: what happened at SAVA last week (0119-0123)?
Weekly Report · 01/26 09:35
Weekly Report: what happened at SAVA last week (0112-0116)?
Weekly Report · 01/19 09:39
Cassava Sciences announces publication of Phase 3 results for simufilam
TipRanks · 01/13 13:10
Cassava Sciences Announces Publication Of Article Phase 3 Randomized Clinical Trials Of Simufilam In Mild-To-Moderate Alzheimer's Disease In Upcoming Issue Of JPAD
Benzinga · 01/13 13:04
Cassava Sciences Publishes Phase 3 Simufilam Alzheimer’s Trial Results in JPAD
Reuters · 01/13 13:01
More
About SAVA
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Webull offers Cassava Sciences Inc stock information, including NASDAQ: SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.